TY - CHAP
T1 - RNAi Treatment of HIV-1 Infection
AU - von Eije, Karin J.
AU - Berkhout, Ben
PY - 2010
Y1 - 2010
N2 - RNA interference (RNAi) is a cellular mechanism that mediates sequence-specific gene silencing by cleavage or translational inhibition of the targeted mRNA. RNAi can be used as an antiviral approach to silence the human immunodeficiency virus type 1 (HIV-1). The first clinical trial using RNAi against HIV-1 in a lentiviral gene therapy setting was initiated in early 2008. In this chapter, we will focus on the basic principles of such an RNAi-based gene therapy against HIV-1. Subjects that will be covered include target site selection within the viral RNA genome, viral escape, and therapeutic strategies to prevent this, such as combinatorial RNAi approaches, systems available for multiplexing of RNAi inhibitors, methods to deliver the antiviral RNAi molecules and gene therapy protocols to achieve durable HIV-1 inhibition. We will also discuss several in vitro and in vivo test systems to evaluate the efficacy and safety of an RNAi gene therapy.
AB - RNA interference (RNAi) is a cellular mechanism that mediates sequence-specific gene silencing by cleavage or translational inhibition of the targeted mRNA. RNAi can be used as an antiviral approach to silence the human immunodeficiency virus type 1 (HIV-1). The first clinical trial using RNAi against HIV-1 in a lentiviral gene therapy setting was initiated in early 2008. In this chapter, we will focus on the basic principles of such an RNAi-based gene therapy against HIV-1. Subjects that will be covered include target site selection within the viral RNA genome, viral escape, and therapeutic strategies to prevent this, such as combinatorial RNAi approaches, systems available for multiplexing of RNAi inhibitors, methods to deliver the antiviral RNAi molecules and gene therapy protocols to achieve durable HIV-1 inhibition. We will also discuss several in vitro and in vivo test systems to evaluate the efficacy and safety of an RNAi gene therapy.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85145218330&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36532858
U2 - https://doi.org/10.1007/978-3-642-12168-5_8
DO - https://doi.org/10.1007/978-3-642-12168-5_8
M3 - Chapter
C2 - 36532858
T3 - RNA Technologies
SP - 191
EP - 208
BT - RNA Technologies
PB - Springer Science and Business Media Deutschland GmbH
ER -